Morphine Added to Ropivacaine for FICB for Postoperative Analgesia

Phase 4

Completed

• Conditions: Postoperative Pain
• Interventions: Drug: Ropivacaine, Morphine; Drug: Ropivacaine, Saline

• Registration Number: NCT03875274
• Lead Sponsor: B.P. Koirala Institute of Health Sciences

Brief Summary

prospective, randomized double blinded study to investigate the effects of morphine as an adjuvant to ropivacaine on FICB

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-01
• Primary Completion: 2017-12-31
• Study Completion: 2017-12-31
• Study First Submitted: 2019-02-01
• Study First Submitted QC: 2019-03-13
• Study First Posted: 2019-03-14
• Results First Submitted: 2021-12-14
• Status Verified: 2022-06
• Results First Submitted QC: 2022-06-14
• Last Update Submitted: 2022-06-14
• Results First Posted: 2023-03-24
• Last Update Posted: 2023-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• All patients undergoing elective femur surgery under spinal anaesthesia

  • Age group (18-65 years)
  • ASA physical status I and II

Exclusion Criteria

• • Not willing to participate in the study

  • Other painful co-morbidities (neuropathies)
  • Allergy or any contraindication to study medication
  • Psychiatric disorder
  • Coagulopathy
  • Infection at the site of the block
  • Use of other modes of anaesthesia or analgesia besides spinal anaesthesia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ropivacaine and morphine group	Ropivacaine, Morphine	Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
Ropivacaine group	Ropivacaine, Saline	Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB

Primary Outcome Measures

Name	Time	Method
Duration of Analgesia	24 hours	The period in minutes when the patient is free of pain

Trial Locations

Locations (1)

BPKIHS; 🇳🇵 Dharān Bāzār, Sunsari, Nepal